Rh-endostatin plus camrelizumab and chemotherapy in first-line treatment of advanced non-small cell lung cancer: A multicenter retrospective study.

Xingxiang PuQianZhi WangLiyu LiuBolin ChenKang LiYu ZhouZengmei ShengPing LiuYucheng TangLi XuJia LiYi KongFang XuYan XuLin Wu

Published in: Cancer medicine (2022)

Rh-endostatin plus camrelizumab and chemotherapy showed favorable efficacy and safety profile in patients with advanced NSCLC, representing a promising treatment regimen for these patients.

Keyphrases

advanced non small cell lung cancer
end stage renal disease
epidermal growth factor receptor
ejection fraction
small cell lung cancer
chronic kidney disease
newly diagnosed
locally advanced
prognostic factors
squamous cell carcinoma
clinical trial
combination therapy
double blind